Comparison of mini-percutaneous nephrolithotomy and standard percutaneous nephrolithotomy in the treatment of renal calculi with renal insufficiency

微创经皮肾镜取石术与标准经皮肾镜取石术治疗肾功能不全合并肾结石的比较

阅读:1

Abstract

To compare the clinical efficacy and safety of mini-percutaneous nephrolithotomy (MPCNL) and standard percutaneous nephrolithotomy (SPCNL) in the treatment of kidney stones combine with renal insufficiency. The data of 320 patients with renal calculi and an eGFR < 60 mL/min/1.73m(2) who underwent percutaneous nephrolithotomy (PCNL) at Zhongshan City People's Hospital from January 2018 to June 2023 were retrospectively analyzed; 164 patients were treated with MPCNL, and 156 were treated with SPCNL. The clinical efficacy of the MPCNL and SPCNL regimens was compared in terms of stone-free rate (SFR), renal function change, hemoglobin (HGB) drop and other complication rates (complications were classified by using the Clavien‒Dindo system). The SFR was 67.1% in the MPCNL group and 67.9% in the SPCNL group (P = 0.867). The overall eGFR of the two groups was significantly improved at 1 month after the operation (P < 0.001). Postoperative renal function was stable, improved and worse in 50.0% (n = 82) vs. 53.8% (n = 84), 39.0% (n = 64) vs. 42.4% (n = 66) and 11.0% (n = 18) vs. 3.8% (n = 6) of the MPCNL and SPCNL patients, respectively, compared with preoperative renal function (P = 0.053). In addition, the overall postoperative complication rates between the two groups was not significantly different (P = 0.103). Patients who underwent MPCNL had a lower transfusion rate (7.9% vs. 16.7%, P = 0.017) and shorter hospital stay (4.57 ± 3.14 vs. 7.16 ± 4.05 days, P < 0.001) than those in the SPCNL group. MPCNL and SPCNL have positive effects on the treatment of renal calculi in patients with renal insufficiency; both have acceptable SFRs and complication rates, stable or improved renal function in most patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。